Epstein-Barr virus may cause and prevent lymphomas
A study published in the Journal of Clinical Investigation may shed new light on the understanding of the link between the Epstein-Barr virus (EBV) and lymphoma.
While it has been known for years that the virus is capable of causing some subtypes of lymphoma, researchers from Imperial College London believe they have uncovered evidence that EBV may also carry not just an oncogene but also its contrary-- a tumor suppressor gene.
The viral gene is known as EBNA3B and researchers are speculating that it may be an evolutionary adaptation that works to keep EBV in check within the cells.
When the dormant virus within the cell does kick-start lymphomas such as Hodgkin's or Burkitt's lymphoma, researchers speculate that some of the time this may be on account of a mutation in EBNA3B.
Source: Sciencenews.org
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
